Question 1

Which Nucleofill density are you recommending and why for my concern?

Accepted Answer

A good answer matches the product to your skin and explains why: "For your concern I'm recommending Nucleofill Medium because it targets the mid-dermis, the deeper structural layer, which is where laxity and skin remodelling work happens." The three densities target different depths: Soft works on surface hydration and texture, Medium addresses mid-dermal laxity, and Strong targets deeper volume support. If they recommend the same density to every patient without examining your skin or asking about your goals, they are not adapting the treatment to you. Injecting at the wrong depth will not reach the problem you came in for.

Question 2

What clinical results have you personally seen in patients similar to me?

Accepted Answer

An honest answer sounds like: "In patients with similar skin I have seen a real improvement in hydration and a mild increase in firmness, usually noticeable around four to six weeks after the first session, but I want to be upfront that this is still an emerging category and the results are more subtle than you would see from something like Sculptra." The key thing you are assessing is whether they are drawing on genuine patient experience or reciting manufacturer brochure language. If their description sounds like a product spec sheet, or they start quoting before-and-after statistics without any caveat about the limited trial data, be sceptical. Nucleofill has a solid mechanistic basis but limited large-scale clinical evidence, and a good provider will acknowledge that.

Question 3

Is this being used as a standalone treatment or in combination with something else?

Accepted Answer

A clear answer explains the plan: "I'm recommending Nucleofill as a standalone treatment here because your primary concern is skin quality and hydration rather than volume loss. If you want to address the volume deficit in your cheeks at a later stage, we can layer in something structural like Sculptra or a filler then." Nucleofill is a biostimulator, meaning it works by signalling your skin cells to regenerate, and it pairs well with structural treatments but cannot substitute for them when real volume loss is the issue. If they recommend Nucleofill for significant hollowing or deep laxity without explaining the limitation, ask explicitly whether it will be enough to address those concerns or whether something structural is also needed.

Question 4

What is the series protocol, how many sessions and how far apart?

Accepted Answer

The standard answer is three to four sessions: "For the initial series I recommend three to four sessions spaced two to four weeks apart, then a maintenance session every six months to sustain the biostimulation." That spacing gives your fibroblasts (the skin cells responsible for making collagen) enough time to respond to each treatment before the next one. If they recommend only one or two sessions for meaningful results, they are shortcutting the protocol. If they want five or more without a clinical explanation, ask what they are basing that on. Significant deviation in either direction without rationale is worth questioning.

Question 5

What peer-reviewed evidence are you basing your recommendation on?

Accepted Answer

The most trustworthy answer is an honest one: "The mechanism is well-established, polynucleotides activate receptors that stimulate fibroblasts and collagen production and that has been confirmed in peer-reviewed research. What we don't yet have are large randomised controlled trials in aesthetic use, so I'm recommending this based on mechanistic evidence and observational clinical data, not on the same level of trial evidence as Botox or Juvederm." A provider who claims the evidence is equivalent to established injectables is misrepresenting the literature. One who cites manufacturer brochures or before-and-after galleries as scientific evidence is not equipped to have an informed consent conversation.

Stay informed